- Unresectable hepatocellular carcinoma:
- PO 400mg BD
- PO 400mg BD
- Advanced renal cell carcinoma:
- PO 400mg BD
- PO 400mg BD
- Refractory differentiated thyroid carcinoma:
- PO 400mg BD
- For patients with locally recurrent or metastatic, progressive disease and who are radioactive iodine-refractory
Tablet: 200mg
To be given at least 1 hour before or 2 hours after food
Tyrosine kinase inhibitor anticancer
It inhibits multiple tyrosine kinases including VEGF and BRAF, resulting in decreased angiogenesis, tumor growth and cancer progression
- Thrombocytopenia
- Anemia
- Diarrhea
- Rash/desquamation
- Fatigue
- Abdominal pain
- Hand-foot skin reaction
- Weight loss
- Anorexia
- Alopecia
- Nausea
- Lymphopenia
- Neutropenia
- Hemorrhage
- Hypertension
- Vomiting
- Constipation
- Neuropathy
- Dry skin
- Headache
- Joint pain
- Squamous cell lung cancer (combo with carboplatin and paclitaxel)
- Squamous cell lung cancer (combo with cisplatin and gemcitabine)
- Breastfeeding during treatment and for 2 weeks after discontinuation
- GI perforation
- Uncorrected electrolyte abnormalities
- Congenital long QT syndrome
- Unhealed surgical wound
- Major surgery within prior 2 weeks
- At least 10 days before an elective surgery
- Dronedarone
- Lefamulin
- Pimozide
- Saquinavir
- Thioridazine
- Ziprasidone
Drug Status
Availability | Prescription only |
Pregnancy | Category D |
Breastfeeding | Contraindicated |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Nexavar | 200mg | Tablet | 60’s, 112’s | Bayer Schering | Bayer Schering |